Pharmacoelectroencephalographic profile of befloxatone, a new reversible mao-a inhibitor, in healthy subjects

Neuropsychobiology

Volumn 34, Issue 2, 1996, Pages 98-105

  Luthringer, R ^a   Dago, K T ^a   Patat, A ^b   Caille, P ^b   Curet, O ^c   Durieu, G ^b   Rinaudo, G ^a   Toussaint, M ^a   Granier, L A ^a   Macher, J P ^a  

^a FORENAP   (France)

^b SANOFI   (France)

^c Centre de Recherche Delalande   (France)

Author keywords

Antidepressants; Befloxatone; Electroencephalography; Event related potential; MAO inhibitors; Pharmaco EEG; Pharmacodynamics

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; BEFLOXATONE; MONOAMINE OXIDASE INHIBITOR;

ADULT; ALPHA RHYTHM; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTROENCEPHALOGRAPHY; EVOKED AUDITORY RESPONSE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; THETA RHYTHM;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS; OXAZOLES;

EID: 10144228405     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119299     Document Type: Article

References (54)

1. Salctu B: Psychopharmaka, Gchimtätigkcil und Schlaf, Karger, München, 1976.
2. Saletu B: The use of pharmaco-EEG in drug profiling; in Hindmarch I, Stonier PD (eds): Human Psychopharmacology, Measures and methods, Chichester, Wiley, 1987, vol 1, pp 173-200.
3. Sannita WG, Cabri M, Montano VF, Rosadini G: Quantitative F.EG and behavioral effects in volunteers of a new benzodiazepine in relation to drug plasma concentration, Thcr Drug Mon-it 1981;3:341-349.
4. Herrmann WM: Development and critical evaluation of an objective procedure for the electroenccphalographic classification of psychotropic drugs: in Hermann WM (ed): EEG in Drug Research, Stuttgart, Fischer, 1982, pp 249-351.
5. Mandema JW, Danhof M: Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs, Clin Pharmacoki-net 1992;23:191-215.
6. Fink M: Cerebral electrometry-quantitative EEG applied to human psychopharmacology; in Dolce G, Kiinkcl H; Computerizing EEG Analysis, Stuttgart, Fischer 1975, pp 171-191.
7. Itil TM: Quantitative pharmaco-elcctroen-cephalography, Use of computerized cerebral biopotentials in psychotropic drug research: in Itil TM (ed): Psychotropic Drugs and the Human EEG, Mod Probl Pharmacopsychiatry, Karger, Basel, 1974, pp 43-75.
8. Matejcek M, Devos JE: Selected methods of quantitative EEG analysis and their applications in psychotropic drug research; in Kclla-way E, Petersen PJ (eds): Quantitative Studies in Epilepsy, New York, Raven Press, 1976, pp 183-205.
9. Matousck M, Hjalntarson A, Koch J, Petersen I: The use of the EEG assessment of vigilance changes caused by beta-blockers, Neuropsychobiology 1984;12:55-59.
10. Engelhardt W, Fricss K, Hartung E, Sold M, Dierks A: EEG and auditory evoked potential P300 compared with psychometric tests in assessing vigilance after benzodiazepine sedation and antagonism, B J Anaesth 1992:69:75-80.
11. Laurian S, Gaillard JM, Le PK, Schöpf J: Topographic aspects of F.EG profile of some psychotropic drugs, Adv Biol Psychiatry 1983:13: 165-171.
12. Saletu B, Grünberger P: Drug profiling by computed electroencephalography and brain maps, with special considerations of sertraline and its psychometric effects, J Clin Psychiatry 1988; 49(suppl):59-71.
13. Itil TM, Pol van M, Hsu W: Clinical and EEG effects of GB94-94 a tetracyclic antidcprcssant: EEG model in discovery of a new psychotropic drug, CurrTherRes 1972;14:395-414.
14. Buchsbaum MS, Hazlctt E, Sicotte N, Stein M, Wu J, Zctin M: Topographic EEG changes with benzodiazepine administration in generalized anxiety disorder, Biol Psychiatry 1985;20:832-842.
15. Coppola R, Herrmann WM: Psychotropic drug profiles: Comparison by topographic maps of absolute power, Neuropsychobiology 1987:8: 97-104.
16. Saletu B, Anderer P, Kinsperger K, Griinberger J: Topographic Brain Mapping of EEG in Psychopharmacology, Part II: Clinical Applications (Pharmaco EEG Imaging), Mctli, and Find, Exptl, Clin Pharmacol 1987:9:385-408.
17. Machcr JP, Luthringer R, Toussaint M, Minot R: Brain mapping and psychoactivc drugs; in Hindmarch I, Stonier PD (eds): Human Psychopharmacology: Methods and Measures, vol 3, 1990.
18. Itil TM, Shapiro DM, Eralp E, Akmann A, Itil KZ, Garbizu C: A new brain function diagnostic unit, including the dynamic brain mapping of computer analyzed EEG, evoked potentials and sleep (a new hardware/software system and its application in psychiatry and psychopharmacology), New Trends Exp Clin Psychiatry 1985;1:107-177.
19. Herrmann WM, Scharer E, Wendt G, Delini-Stula A: Pharmaco-EEG profile of maroxepine: Third example to discuss the predictive value of pharmaco-electroencephalography in early human pharmacological evaluations of psychoactive drugs, Pharmacopsychiatry 1991:24: 214-224.
20. Herrmann WM, Scharer E, Wendt G, Delini-Stula A: Pharmaco-EEG profile of lcvoproti-line: Second example to discuss the predictive value of pharmaco-eleclroencephalography in early human pharmacological evaluations of psychoactive drugs, Pharmacopsychiatry 1991; 24:206-213.
21. Salctu B, Griinberger J, Kinzmayer L: Is ame-zinium mctilsulfate-a new antihypotensive drug psychoactive? Comparative quantitative EEG and psychometric trials with desipraminc and methamphctamine, Curr Ther Res 1985: 28:800-826.
22. Salctu B, Griinberger J, Linzmayer L, Tacuber K: The pharmacokinetics of nominfensine, Comparison of pharmacokinetics and pharmacodynamics using computer pharmaco-EEG, Int Pharmacopsychiatry 1982:17:43-72.
23. Saletu B, Griinberger J: Classification and determination of cerebral bioavailability of fluoxetine: Pharmacokinetic, pharmaco-EEG and psychometric analyses, J Clin Psychiatry 1985; 46:45-52.
24. Salctu B, Griinberger J, Linzmayer L: On central effects of scrotonine re-uptake inhibitors: Quantitative EEG and psychometric studies with sertraline and zimelidinc, J Neural Transm 1986;67:241-266.
25. Da Prada M, Kcttler HH, Burkard WP, Muggli-Maniglio D, Haefely WE: Neurochemical profile of moclobemide, a short acting a reversible inhibitor of monoamine oxydase type A, J Pharmacol Exp Ther 1989:248:400-414.
26. Waldmeier PC, Felner AE, Tipton KF: The monoamine oxidase inhibiting properties of CGP 1 1305, Eur J Pharmacol 1983;94:73-83.
27. Fowler CJ, Ross SB: Selective inhibitors of monoamine oxidase A and B: Biochemical and clinical properties, Med Res Rev 1984:4:323-358.
28. Rovei V, Caille D, Curet O, Ego D, Jarrcau FX: Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor, J Neural Transm 1994;41 (suppl): 339-347.
29. Herrmann WM, Abt K, Coppola R, Etevenon P, Fcrher G, Fink M, Gcvins AS, Hinrichs II, Itil TM, John ER, Kubicki St, Künkel II, Kug-ler J, Lehmann D, Petsche H, Rappclsbergcr P, Röhmel J, Saito M, Saletu B, Schculer W: International Pharmaco-EEG Group (IPEG), Recommendations of EEG and evoked potential mapping, Neuropsychobiology 1989:22:170-176.
30. Jasper HH: The ten twenty electrode system of the International Federation, Electrocncepha-logrClin Ncurophysiol 1958:10:371-375.
31. Cooley JW, Tuckey JW: An algorithm for the machine calculation of complex Fourier series, Math Comp 1965:19:297-301.
32. Matejcek M: Cortical correlates of vigilance regulation and their use in evaluating the effects of treatment, Adv Biochem Psychophar-maco! 1980:23:339-348.
33. SoulTlet I., Toussaint M, Luthringcr R, Koudou DT, Gresscr J, Minot R, Macher JP: A statistical evaluation of the main interpolation methods applied to three dimensional EEG mapping, Electrocnccphalogr Clin Neurophysiol 1991;79:393-402.
34. Bond A, Lader M: The use of analogue scales in rating subjective feelings, Br J Med Psychol 1974;47:24-218.
35. McNair DM, Lorr M, Droppleman LF: Manual for the Profile of Mood States, Educational and Industrial Testing Service, San Diego, 1971.
36. Dago KT, Luthringcr R, Lcngelle R, Rinaudo G, Macher JP: Statistical decision tree: A tool for studying pharmaco-EEG effects of CNS-active drugs, Neuropsychobiology 1994:29:91-96.
37. Riederer P, Laux G, Beckmann H, Salctu B, Waldmeier P, Fritze J, DaPrada M, Möller HJ, Sehmauss M, Przuntck H: The new generation of selective monoamine oxidase-inhibitors: biochemical, pharmacological and clinical perspectives, Pharmacopsychiatry 1988:21:283-284.
38. Minot R, Luthringer R, Machcr JP: Effect of moclobemide on the psychophysiology of sleep/wake cycles: A ncuroelcctrophysiological study of depressed patients administered with moclobemide, Int Clin Psychopharmacol 1993; 7:181-189.
39. Möller HJ, Wendt G, Waldmeier P: Brofaro-mine-a selective, reversible, and short-acting MAO-A inhibitor: Review of the pharmacological and clinical findings, Pharmacopsychiatry 1991;24:50-54.
40. Barbanoj MJ, Andercr P, Antonijoan J, Torrent J, Saletu B, Jane F: Human Psvehophar-macol 1994:9:101-109.
41. Saito A, Kinoshita T, Yagyu T, Saito M, Schollnhammer G: Quantitative pharmaco-EEG study of ipsapirone, 6th IPEG Symp, Göteborg, 1990.
42. Lulhringer R, Minot R, Toussaint M, Macher JP: EEG and EP mapping of a new 5 HT AD: Stablon, Biol Psychiatry 1989;25:159.
43. Blier P, De Montigny C, Azzaro AJ: Modification of serotoninergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors: Electrophysio-logical studies in the rat central nervous system, J Pharmacol Exp Ther 1986:237:987-994.
44. Curet O, Damoiseau G, Labaune JP, Rovei V, Jarreau FX: Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats, J Neural Transm 1994:41 (suppl):349-355.
45. McCarthy G, Donchin E: A metric for thought: A comparison between P3 latency and reaction time, Science 1981:211:77-80.
46. Plourde G: Depth of anesthesia, Can J Anacsth 1991:38:270-274.
47. Squires K.C, Petruchowski S, Wickcns C, Donchin E: The effects of stimulus sequence on event-related potentials: a comparison of visual and auditory sequences, Percept Psychophys 1977;22:31-40.
48. Sutton S, Braren M, Zubin J, John ER: Evoked potential correlates of stimuli uncertainty, Science, 1965;150:1187-1188.
49. Squires NK, Squires KG, Hillyard SA: Two varieties of long latency positive waves to unpredictable auditory stimuli, Elcctroencepha-logrClin Ncurophysiol 1975:38:387-401.
50. Rohrbaugh JW, Gaillard AWK: Sensory and motor aspects of the contingent negative variation; in Gaillard ANK, Ritter JW (eds): Tutorials in ERP Research: the Endogenous Components Amsterdam, North-Holland, 1983
51. Teccc JJ: CNV and psychological processes in man, Psychol Bull 1972:77:73-108.
52. Saletu B, Griinberger J, Andcrer P, Linzmaver L, Scmlitsch HV, Magni G: Pharmacodynamics of venlafaxinc evaluated by EEG brain mapping, psychomctry and psychophysiology, Br J Clin Pharmacol 1992;33:589-601.
53. MacCrimmon DJ, Arato M: Interhemispheric serotoninergic asymmetry reflected in topographic pharmaco-EEG, Psychiatry Res 1991: 40:91-93.
54. Davidson RJ: EEG measures of cerebral asymmetry: Conceptual and methodological issues, IntJNeurosci 1987:39:69-71.